{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the 95% CI for the median had not yet been reached at time of analysis.","groupId":"OG000","lowerLimit":"42","upperLimit":"NA","value":"68"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"}],"units":"Participants"}],"description":"Time from initial registration until death or date of last contact, whichever occurs first, for up to 5 years from the date of the last patient registration.","dispersionType":"95% Confidence Interval","groups":[{"description":"MM Induction: dexamethasone 20mg/d PO Days 1-4, 9-12 and 17-20 every 35 days for 2 cycles and thalidomide 200 mg/d PO Days 1-70.\n\nMobilization and SC Collection: MM, MM+AL, MM+LCD: cyclophosphamide 2.5 gm/m2 IV Day 1; mesna 800 mg/m2 IV Day 1 x 3 doses; G-CSF 10 mcg/kg/d SQ Day 2 through day prior to last leukapheresis.\n\nAmyloid or LCDD-Only: G-CSF 16 mcg/kg/d SQ Days 1-3 (continued daily until the day prior to the last day of stem cell collection).\n\nConditioning/Transplant - Modified HighDose Melphalan (given for both transplants): melphalan 100 mg/m2/d IV over 20 mins Day -2; PBSC infusion \\>/= 3.5 x 10\\^6 CD34+ cells/kg IV Day 0.\n\nMaintenance (MM only): dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year, followed by dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year.\n\nfilgrastim\n\ncyclophosphamide\n\ndexamethasone\n\nmelphalan\n\nthalidomide\n\nperipheral blood","id":"OG000","title":"Treatment"}],"paramType":"MEDIAN","populationDescription":"Eligible and analyzable patients only.","reportingStatus":"POSTED","timeFrame":"5 years from initial registration, or until death, whichever occurred earlier, on average, about 4.5 years","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"Months"}